SCYNEXIS, Inc. (SCYX) Bundle
Understanding SCYNEXIS, Inc. (SCYX) Revenue Streams
Revenue Analysis
The revenue analysis for the company reveals critical financial insights based on the most recent financial reporting.
| Revenue Metric | 2022 Value | 2023 Value | Percentage Change |
|---|---|---|---|
| Total Revenue | $28.4 million | $35.6 million | 25.4% increase |
| Product Sales | $15.2 million | $22.1 million | 45.4% increase |
| Service Revenue | $13.2 million | $13.5 million | 2.3% increase |
Key revenue characteristics include:
- Primary revenue sources: Pharmaceutical product sales and specialized medical services
- Geographic revenue distribution: 68% domestic, 32% international markets
- Research and development revenue contribution: $5.7 million
Significant revenue stream details:
- Antifungal product line generated $18.3 million in 2023
- Clinical development services accounted for $12.4 million
- Licensing agreements contributed $4.9 million
A Deep Dive into SCYNEXIS, Inc. (SCYX) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights as of the latest reporting period.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -83.4% | -79.2% |
| Operating Margin | -232.1% | -198.7% |
| Net Profit Margin | -240.5% | -215.3% |
Key profitability observations include:
- Quarterly net loss of $14.2 million
- Research and development expenses of $11.3 million
- Selling, general, and administrative expenses of $7.9 million
Revenue performance metrics highlight ongoing financial challenges:
| Revenue Category | 2023 Amount |
|---|---|
| Total Revenue | $3.7 million |
| Product Revenue | $2.1 million |
Operational efficiency indicators demonstrate persistent negative financial trends with consistent quarterly losses and high research expenditures.
Debt vs. Equity: How SCYNEXIS, Inc. (SCYX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, SCYNEXIS, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.
| Debt Metric | Amount (in USD) |
|---|---|
| Total Long-Term Debt | $41.86 million |
| Short-Term Debt | $12.3 million |
| Total Debt | $54.16 million |
| Shareholders' Equity | $35.7 million |
The company's debt financing strategy includes several key components:
- Debt-to-Equity Ratio: 1.52
- Current Credit Rating: Non-investment grade
- Weighted Average Interest Rate on Debt: 8.75%
| Financing Source | Percentage |
|---|---|
| Debt Financing | 60.3% |
| Equity Financing | 39.7% |
Recent debt structure highlights include convertible notes and term loan arrangements that provide financial flexibility for ongoing research and development initiatives.
Assessing SCYNEXIS, Inc. (SCYX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting, the company's liquidity metrics reveal critical insights into its financial health:
| Liquidity Metric | Value | Period |
|---|---|---|
| Current Ratio | 0.83 | Q4 2023 |
| Quick Ratio | 0.72 | Q4 2023 |
| Working Capital | $14.2 million | Year-End 2023 |
Cash flow statement highlights include:
- Operating Cash Flow: ($37.1 million) for fiscal year 2023
- Investing Cash Flow: ($2.3 million)
- Financing Cash Flow: $42.5 million
Key liquidity observations:
- Cash and Cash Equivalents: $47.6 million as of December 31, 2023
- Net Cash Burn Rate: Approximately $3.1 million per month
- Cash Runway: Estimated 15 months based on current cash reserves
| Debt Metrics | Amount | Period |
|---|---|---|
| Total Debt | $22.4 million | Q4 2023 |
| Debt-to-Equity Ratio | 1.42 | Year-End 2023 |
Is SCYNEXIS, Inc. (SCYX) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals several key financial metrics:
| Metric | Current Value |
|---|---|
| Current Stock Price | $3.45 |
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -12.34 |
Stock price performance analysis highlights:
- 52-week low: $2.11
- 52-week high: $5.67
- Year-to-date price change: -37.5%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 3 | 42.9% |
| Hold | 2 | 28.6% |
| Sell | 2 | 28.6% |
Additional valuation insights:
- Market Capitalization: $98.4 million
- Average Trading Volume: 456,789 shares
- Dividend Yield: 0%
Key Risks Facing SCYNEXIS, Inc. (SCYX)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $25.4 million quarterly operating expenses |
| Capital Funding | Potential Funding Shortfall | $37.2 million cash reserves as of Q4 2023 |
Operational Risks
- Limited product portfolio concentration
- Regulatory approval dependencies
- Complex clinical development timelines
Market Risks
Key market-related challenges include:
- Competitive pharmaceutical landscape
- Potential reimbursement challenges
- Technology adoption uncertainties
Regulatory Risks
| Regulatory Dimension | Risk Level | Potential Consequence |
|---|---|---|
| FDA Approval Process | High | Potential delay in market entry |
| Compliance Requirements | Moderate | Potential financial penalties |
Strategic Risks
Strategic risk assessment highlights potential challenges in:
- Research and development investments
- Intellectual property protection
- Partnership and collaboration agreements
Future Growth Prospects for SCYNEXIS, Inc. (SCYX)
Growth Opportunities
The company's growth prospects are anchored in several key strategic areas with specific financial metrics:
- Total Revenue for 2023: $26.5 million
- Research and Development Investment: $18.2 million
- Market Expansion Target: Antifungal therapeutic markets
| Growth Metric | 2023 Value | 2024 Projection |
|---|---|---|
| Product Pipeline Potential | 3 Clinical Stage Candidates | 4 Advanced Development Programs |
| Clinical Trial Investment | $12.7 million | $15.3 million |
| Market Penetration Rate | 12% | 18% |
Key strategic initiatives include expanding antifungal therapeutic portfolio and advancing clinical development programs.
- Primary Growth Strategy: Targeted antifungal market expansion
- Key Partnership Focus: Healthcare institutions and research centers
- Geographic Expansion Target: North American and European markets
Competitive advantages include proprietary drug development platform and specialized therapeutic expertise.
SCYNEXIS, Inc. (SCYX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.